Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Buy" from Analysts

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have received a consensus recommendation of "Buy" from the nine ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $35.71.

A number of research analysts recently issued reports on the stock. Bank of America raised shares of Day One Biopharmaceuticals from an "underperform" rating to a "buy" rating and lifted their price objective for the company from $11.00 to $24.00 in a research note on Thursday, August 1st. JPMorgan Chase & Co. decreased their target price on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 6th. TD Cowen raised shares of Day One Biopharmaceuticals to a "strong-buy" rating in a research note on Monday, November 4th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st.

Insider Buying and Selling

In related news, insider Samuel C. Blackman sold 10,000 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $16.10, for a total value of $161,000.00. Following the transaction, the insider now owns 1,057,535 shares in the company, valued at $17,026,313.50. The trade was a 0.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 51,745 shares of company stock valued at $775,867 over the last 90 days. 8.40% of the stock is owned by insiders.

Institutional Trading of Day One Biopharmaceuticals

A number of large investors have recently bought and sold shares of DAWN. Mirae Asset Global Investments Co. Ltd. grew its stake in Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company's stock worth $51,000 after purchasing an additional 1,002 shares during the period. Quest Partners LLC grew its stake in Day One Biopharmaceuticals by 9,238.6% during the third quarter. Quest Partners LLC now owns 7,751 shares of the company's stock worth $108,000 after purchasing an additional 7,668 shares during the period. SG Americas Securities LLC acquired a new stake in Day One Biopharmaceuticals during the second quarter worth approximately $113,000. Point72 DIFC Ltd acquired a new stake in Day One Biopharmaceuticals during the second quarter worth approximately $124,000. Finally, Hsbc Holdings PLC acquired a new stake in Day One Biopharmaceuticals during the second quarter worth approximately $163,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Price Performance

NASDAQ:DAWN traded up $0.18 during mid-day trading on Thursday, reaching $13.72. The stock had a trading volume of 584,189 shares, compared to its average volume of 956,040. The stock has a 50-day simple moving average of $14.35 and a two-hundred day simple moving average of $14.18. The stock has a market capitalization of $1.38 billion, a PE ratio of -13.32 and a beta of -1.51. Day One Biopharmaceuticals has a 12 month low of $11.30 and a 12 month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.58. The firm had revenue of $93.76 million during the quarter, compared to the consensus estimate of $15.05 million. During the same period last year, the business earned ($0.54) earnings per share. Equities analysts expect that Day One Biopharmaceuticals will post -0.88 EPS for the current year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.